NASDAQ
15.04.25
19:38 Uhr
8,010 US-Dollar
+0,280
+3,62 %
+3,62 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.02. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results | 102 | GlobeNewswire (Europe) | Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an... ► Artikel lesen | |
| 27.02. | Cullinan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.02. | Cullinan Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 27.02. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.01. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.01. | Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have ... | 107 | PR Newswire | TOKYO, PRINCETON, N.J. and CAMBRIDGE, Mass., Jan. 28, 2025 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the... ► Artikel lesen | |
| 14.11.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | 215 | GlobeNewswire (Europe) | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| 07.11.24 | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.24 | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 | 1 | GlobeNewswire (USA) | ||
| 24.10.24 | UBS sees upside in Cullinan Oncology stock as key trials approach | 5 | Investing.com | ||
| 24.10.24 | UBS sieht Potenzial in Cullinan Oncology-Aktie vor wichtigen Studien | 2 | Investing.com Deutsch | ||
| 17.10.24 | Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval | 1 | Investing.com | ||
| 17.10.24 | Cullinan Oncology: H.C. Wainwright erhöht Kursziel um 5% und bleibt nach FDA-Zulassung optimistisch | 1 | Investing.com Deutsch | ||
| 16.10.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus | 105 | GlobeNewswire (Europe) | CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.... ► Artikel lesen | |
| 17.09.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus | 172 | GlobeNewswire (Europe) | Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus The trial will be conducted in multiple... ► Artikel lesen | |
| 14.09.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 | 559 | GlobeNewswire (Europe) | Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations... ► Artikel lesen | |
| 01.06.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib | 168 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced... ► Artikel lesen | |
| 15.05.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | 352 | GlobeNewswire (Europe) | Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases... ► Artikel lesen | |
| 29.04.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | 303 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,175 | +0,11 % | Qiagen-Aktie +2%: Gutes Investment in unsicheren Zeiten? | Die Qiagen-Aktie ist zu Wochenbeginn gegen den Trend um mehr als +2% auf 36,15 € gestiegen. Sie war damit am Schwarzen Montag nur einer von zwei DAX-Titeln im Gewinn. Was sind die Gründe für diese relative... ► Artikel lesen | |
| MURAL ONCOLOGY | 2,600 | +157,43 % | Raymond James cuts Mural Oncology target to $4, retains outlook | ||
| BIONTECH | 88,05 | -2,44 % | Biotech Report: Evotec und Biontech drehen nach oben | (shareribs.com) Frankfurt / New York 08.04.2024 - Biotech-Aktien bewegten sich im deutschen Handel überwiegend im Plus. Der Sektor profitiert von einer breiten Erholung. An der Wall Street zeigt sich... ► Artikel lesen | |
| EVOTEC | 5,944 | +2,80 % | Bayer, BioNxt Solutions, Evotec - falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? | Die vorläufige Zollausnahme für Medikamente und pharmazeutische Produkte bietet der Branche eine Atempause - doch der Schein trügt. Gestützt auf WTO-Regeln schützen die Ausnahmen zwar deutsche Exporte... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,700 | -9,30 % | Here's Why Summit Therapeutics Stock Soared 15% on Friday | ||
| TEMPUS AI | 41,825 | -2,89 % | Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) and Tempus AI, Inc. (TEM), Tuesday announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,770 | +4,11 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,010 | +21,60 % | Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 | Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102... ► Artikel lesen | |
| DOGWOOD THERAPEUTICS | 4,045 | +34,83 % | Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance | ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,585 | +1,55 % | Recursion Pharmaceuticals: Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas | Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first... ► Artikel lesen | |
| BB BIOTECH | 28,950 | 0,00 % | BB Biotech packt bei eigenen Aktien die Torschlusspanik | ||
| VIKING THERAPEUTICS | 20,135 | -6,83 % | Wall Street mit Schwung erwartet - Goldman Sachs, Pfizer, Viking Therapeutics, Best Buy, Nvidia, AMD | Nach einer Woche mit außergewöhnlich starken Kursschwankungen haben die US-Börsen zum Handelsende hin deutlich zugelegt. Alle großen US-Indizes konnten im Verlauf ins Plus drehen. Der Dow Jones schloss... ► Artikel lesen | |
| VALNEVA | 3,208 | +1,45 % | Valneva testet Shigella-Impfstoff S4V2 in Phase 2 | Valneva hat gemeinsam mit LimmaTech die erste Impfung im Rahmen einer pädiatrischen Phase-2-Studie mit dem Shigellen-Impfstoffkandidaten S4V2 vorgenommen. Die Studie untersucht an rund 110 Säuglingen... ► Artikel lesen | |
| STRYKER | 308,30 | -1,00 % | Stryker Corporation (SYK): A Bull Case Theory | ||
| SPRINGWORKS THERAPEUTICS | 37,460 | +0,04 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen |
Das Unternehmen CULLINAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,280 (+3,62 %) liegt der Kurs bei 8,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.
